<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13582">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02930109</url>
  </required_header>
  <id_info>
    <org_study_id>PTX-200-AML-015</org_study_id>
    <nct_id>NCT02930109</nct_id>
  </id_info>
  <brief_title>A Study of PTX-200 (Triciribine) Plus Cytarabine in Refractory or Relapsed Acute Leukemia</brief_title>
  <official_title>A Phase I-II Study of Triciribine Phosphate Monohydrate (PTX-200) Plus Cytarabine in Refractory or Relapsed Acute Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prescient Therapeutics, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Prescient Therapeutics, Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase I-II open label study of PTX-200 in combination with cytarabine in the treatment of
      relapsed or refractory acute leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design: Phase I/II study The Phase I study is open-label with four increasing dose
      levels for up to four 21-day cycles. Safety and activity will be evaluated at the end of
      each cycle.

      The Phase II study is open label with administration of the recommended phase dose of
      PTX-200 for up to four 21-day cycles. PTX-200 will be co-administered with cytarabine in
      both the Phase I and Phase II parts of the study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related Adverse Events as assessed by CTCAE v4.0 that result in dose-limitations (Phase I)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline phospho-Akt (pAkt) expression within CD34+ leukemic blasts and the ability of PTX-200 to downregulate p-Akt and its signaling at a variety of times</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline phospho-Akt (pAkt) signaling within CD34+ leukemic blasts and the ability of PTX-200 to downregulate p-Akt and its signaling at a variety of times</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Acute Leukemia</condition>
  <arm_group>
    <arm_group_label>PTX-200 and cytarabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PTX-200 administered intravenously over 1 hour
Phase I: 4 dose levels: 25 to 55 mg/m2 (with reduction to 15 mg/m2 if needed.
Phase II: maximum tolerated dose. given as a 1 hour infusion
Cytarabine administered by continuous infusion at a dose of 400 mg/m2/day for 4 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PTX-200</intervention_name>
    <description>During the Phase I study, increasing dose levels of PTX-200 will be administered as an intravenous infusion on days 1, 8 and 15 of each cycle. Triciribine will be infused over 1 hour on days 1, 8, and 15 of each 21 day cycle. The initial dose level will be 25 mg/m2 and each dose level will be increased by 10 mg/m2 to a maximum dose of 55 mg/m2</description>
    <arm_group_label>PTX-200 and cytarabine</arm_group_label>
    <other_name>Triciribine Phosphate Monohydrate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Cytarabine will be given at a dose of 400mg/m2 as a continuous IV infusion on days 2-6 of each cycle.</description>
    <arm_group_label>PTX-200 and cytarabine</arm_group_label>
    <other_name>Ara-C</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologic confirmation of the diagnosis of AML, ALL (acute lymphoblastic leukemia),
             or blast-phase CML (chronic myelogenous leukemia)

          -  Age ≥ 18 years

          -  ECOG Performance Status 0-2

          -  Patients must be able to give adequate informed consent

        Exclusion Criteria:

          -  Hyperleukocytosis with ≥ 30,000 leukemic blasts/µL blood (hydroxyurea permitted up to
             24 hours prior to beginning study drugs)

          -  Uncontrolled Disseminated Intravascular Coagulation (DIC)

          -  Uncontrolled diabetes mellitus

          -  Active, uncontrolled infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Lancet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Moffitt Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mandeep Grewal</last_name>
    <email>mandeep@ptxtherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Hillgruber</last_name>
      <email>nancy.hillgruber@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Lancet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 7, 2016</lastchanged_date>
  <firstreceived_date>September 13, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cytarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
